

One therapy with many attributes
POTENT DIFLUORINATED STEROID
With fluorination at the C-6 and C-9 positions1
EMULSION FORMULATION FOR DOSE
CONSISTENCY1,10
The only topical ophthalmic steroid formulated as an emulsion, and with proprietary DROP-TAINER® technology1
BAK-FREE TOPICAL OPHTHALMIC STEROID
Preserved with sorbic acid1
CONSISTENT DRUG DELIVERY10
Regardless of bottle orientation or shaking, all DUREZOL® Emulsion concentrations at each time point analyzed were within 15% of declared concentration.10
Percent variation in concentration of active drug dispensed
In clinical studies of cataract surgery patients
Proven to help clear inflammation and resolve ocular pain1
ZERO INFLAMMATION IN NEARLY 3X MORE PATIENTS VERSUS PLACEBO1,11
Percentage of patients with anterior chamber cells clearing (cell count=0)
ZERO PAIN IN NEARLY 2X AS MANY PATIENTS VERSUS PLACEBO1,11
Percentage of patients who were pain free


Help resolve inflammation in patients with endogenous anterior uveitis
For the noninferiority analysis, the upper 95% CL on the difference in mean change from baseline in AC cell grade was required to be <0.5 units. The difference was less than the noninferiority margin at all time points after Day 3.13
Mean change from baseline in AC cell grade13
Study treatment-related ocular adverse events for patients with endogenous anterior uveitis13,14
Study 113
Adverse Event |
DUREZOL® Emulsion |
Pred Forte* Suspension |
---|---|---|
Punctate keratitis |
8 (16.0) |
5 (12.5) |
Vision blurred |
4 (8.0) |
0 (0.0) |
Iridocyclitis |
— |
— |
Eye irritation |
5 (10.0) |
1 (2.5) |
Dry eye |
3 (6.0) |
0 (0.0) |
IOP increase† |
6 (12.0) |
2 (5.0) |
Study 214,15
Adverse Event |
DUREZOL® Emulsion |
Pred Forte* Suspension |
---|---|---|
Punctate keratitis |
3 (5.4) |
0 (0.0) |
Vision blurred |
1 (1.8) |
0 (0.0) |
Iridocyclitis |
3 (5.4) |
2 (3.7) |
Eye irritation |
1 (1.8) |
0 (0.0) |
Dry eye |
— |
— |
IOP increase† |
5 (8.9) |
2 (3.7) |
*Trademark is the property of its owner.
†IOP increases that were reported as an adverse event (which may not have been captured as a “clinically significant IOP rise,” or one that was ≥21 mmHg and change from baseline ≥ 10 mmHg at the same visit).


Safety profile for patients based on ocular surgery clinical trials
Study treatment-related ocular adverse events occurring in more than 2% of patients.1,11
CONJUNCTIVAL HYPEREMIA
DUREZOL®
Emulsion, 4x daily
4.5%
Placebo
19.5%
CILIARY HYPEREMIA
DUREZOL®
Emulsion, 4x daily
4.5%
Placebo
17.3%
ANTERIOR CHAMBER CELL
DUREZOL®
Emulsion, 4x daily
3.6%
Placebo
11.8%
CONJUNCTIVAL EDEMA
DUREZOL®
Emulsion, 4x daily
3.6%
Placebo
6.4%
EYE INFLAMMATION
DUREZOL®
Emulsion, 4x daily
1.8%
Placebo
3.6%
PHOTOPHOBIA
DUREZOL®
Emulsion, 4x daily
3.6%
Placebo
5.5%
PUNCTATE KERATITIS
DUREZOL®
Emulsion, 4x daily
3.6%
Placebo
2.7%
ANTERIOR CHAMBER FLARE
DUREZOL®
Emulsion, 4x daily
0.9%
Placebo
7.3%
IRITIS
DUREZOL®
Emulsion, 4x daily
2.7%
Placebo
0.5%
VISUAL ACUITY REDUCED
DUREZOL®
Emulsion, 4x daily
4.5%
Placebo
8.6%
EYE PAIN
DUREZOL®
Emulsion, 4x daily
5.4%
Placebo
5.0%
FOREIGN BODY SENSATION
DUREZOL®
Emulsion, 4x daily
0.9%
Placebo
4.1%
CORNEAL EDEMA
DUREZOL®
Emulsion, 4x daily
2.7%
Placebo
8.2%
In clinical trials of ocular surgery, the mean IOP in patients receiving DUREZOL® Emulsion did not significantly change and remained in the normal range in all treatment groups11
A clinically significant IOP rise (≥21 mmHg; ≥10 mmHg from baseline) was observed in 3 patients (3%) in the DUREZOL® Emulsion QID group and in 2 patients (1%) in the placebo group.11
When DUREZOL® Emulsion is used for 10 days or longer, IOP should be monitored.1
One patient in the DUREZOL® Emulsion groups and both patients in the placebo group required lOP-lowering medication.11
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve and defects in visual acuity and fields of vision. 1
ST-601A-002a and ST-601A-002b
Clinical trial: IOP range11
Observed IOP increase in clinical trials of EAU:
- 6 patients (12%) in the DUREZOL® Emulsion group and 2 patients (5%) in the prednisolone acetate group in Study 113,15
- 5 patients (8.9%) in the DUREZOL® Emulsion group and 2 patients (3.7%) in the prednisolone acetate group in Study 213,15
Proportion of patients with a single-visit change in IOP of ≥10 mmHg from baseline and an observed value of ≥21 mmHg
ST-601A-002a and ST-601A-002b
Clinical trial: IOP Change–DUREZOL® Emulsion vs. Pred Forte*
*Trademark is the property of its owner.

$60
for a 5.0 ml bottle
Your patients will:
- Receive the medication you prescribe.
- Not have to spend time trying to figure out their prescription coverage.
- Be able to pick up at any one of the 54,000+ participating pharmacies.
To learn the full details of MyChoiceRx™ and how it can benefit your patients, please visit MyChoiceRx.com or call 1-866-747-4276.
* Valid prescription required. Purchases through the Program may not be counted toward patient deductible or out-of-pocket costs. Patients with federal or state-funded prescription plans (i) may not seek reimbursement from their plan for Program purchases, (ii) must notify plan of participation through provided form letter, and (iii) must not use their plan benefits for the remainder of the calendar year for any subsequent purchase of the Novartis product purchased through the Program. Program is not insurance. Patient is responsible for complying with applicable requirements of their plan. Valid only in the United States and Puerto Rico. Limitations may apply in CA and MA. Void where prohibited by law. Novartis reserves the right to rescind, revoke, or amend Program without notice. If you have any questions pertaining to the MyChoiceRx program, including questions regarding the transmission of a claim, reimbursement, or about patient eligibility, please e-mail ScriptHero at help@scripthero.com.
